The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Study Type
OBSERVATIONAL
Enrollment
1,500
Clinical Trial Site
La Jolla, California, United States
RECRUITINGClinical Trial Site
Los Angeles, California, United States
RECRUITINGClinical Trial Site
Jacksonville, Florida, United States
RECRUITINGClinical Trial Site
Iowa City, Iowa, United States
RECRUITINGClinical Trial Site
Kansas City, Kansas, United States
RECRUITINGClinical Trial Site
Baltimore, Maryland, United States
RECRUITINGClinical Trial Site
Boston, Massachusetts, United States
COMPLETEDClinical Trial Site
New York, New York, United States
RECRUITINGClinical Trial Site
Durham, North Carolina, United States
RECRUITINGClinical Trial Site
Columbus, Ohio, United States
RECRUITING...and 30 more locations
Incidence of Adverse Events
Time frame: From time of enrollment for up to 10 years
Selected Events of Interest in Patients with Hereditary Transthyretin-mediated (hATTR) Amyloidosis (ATTRv Amyloidosis)
Selected events of interest are defined as hepatic events, cardiovascular events, renal events, ocular events and infusion-related reactions, hypersensitivity, and other events in patients diagnosed with hATTR amyloidosis.
Time frame: From 1 year prior to enrollment for up to 10 years
Health Care Provider (HCP)-Assessed Polyneuropathy (PND) Disability Score
PND Scores: Stage 0=No symptoms; Stage I=Sensory disturbances but preserved walking capabilities; Stage II=Impaired walking capacity, but ability to walk without a stick or crutches; Stage IIIA=Walking with help of 1 stick or crutch; Stage IIIB=Walking with the help of 2 sticks or crutches; Stage IV=confined to wheel chair or bedridden.
Time frame: Up to 11 years
HCP-Assessed Familial Amyloidotic Polyneuropathy (FAP) Score
FAP Scores: Stage 0=No symptoms; Stage I=Unimpaired ambulation; mostly mild sensory, motor and autonomic neuropathy in the lower limbs; Stage II=Assistance with ambulation required, mostly moderate impairment progression to the lower limbs, upper limbs, and trunk; Stage III=Wheelchair-bound or bedridden; severe sensory, motor, and autonomic involvement of all limbs.
Time frame: Up to 11 years
HCP-Assessed Neuropathy Impairment Score (NIS)
NIS : 74 items, assess muscle weakness, reflexes and sensation; scored separately for left, right limbs (37 items for each side). Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS score range 0-244, higher score=greater impairment.
Time frame: Up to 11 years
HCP-Assessed Cardiomyopathy
Cardiomyopathy will be assessed using New York Heart Association (NYHA) Class: I=No symptoms; II=Symptoms with ordinary physical activity; III=Symptoms with less than ordinary physical activity; IV=Symptoms at rest.
Time frame: Up to 11 years
HCP- Assessed Cardiopulmonary Exercise Testing (CPET) Performance
Time frame: Up to 11 years
Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score
Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life).
Time frame: Up to 11 years
Kansas City Cardiomyopathy Questionnaire (KCCQ)
The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary \[OS\] scores).
Time frame: Up to 11 years
Rasch-built Overall Disability Scale (R-ODS)
The R-ODS is a 24-item self-administered questionnaire for assessment of the disability a patient experiences. It uses a linearly weighted categorical rating scale that specifically captures domains of activity and social participation limitations in patients.
Time frame: Up to 11 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.